Merck Temporarily Suspends Stimuvax Clinical Program
The Germany-based pharma company said that the decision was taken in alignment with the FDA’s clinical hold placed on the investigational new drug (IND) application for Stimuvax. In
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.